Menarini/Stemline
- Menarini and its subsidiary, Stemline were awaiting U.S. FDA approval for elacestrant ORSERDU™, a first and only oral endocrine therapy that treats advanced or metastatic breast cancer (mBC)
- Create market shaping, visibility and awareness through broad coverage in oncology, medical and trade media publications highlighting the drug, its clinical benefits and opportunities for success as an mBC treatment
- Use the Company’s first U.S. approval since acquiring Stemline to drive visibility for the Menarini Stemline Oncology division in U.S.
LHS Solutions
- Conducted LHS Immersion® to solidify corporate and brand messaging and create the basis for strong storylines to key audiences
- Identified market misperceptions and corrected them through direct engagement
- Built communication strategies to educate HCP audiences on the clinical significance of the Phase 3 EMERALD results at key medical meetings
- Increased U.S. brand awareness and reputation by creating foundational relationships with key oncology, medical and industry journalists
- Developed media room materials including, fact sheets, FAQs, holding statement, biographies and images for a multimedia press release
- Prepared the KOLs for interviews
Results
- Cohesive, integrated communication strategy that successfully exceeded KPIs – securing articles in 91% of oncology and industry trade pubs including Targeted Oncology, OncLive, OBR, Cure, Healio, FiercePharma, BioCentury, BioWorld, EveryDay Health
- Positioned ORSERDU as the first new endocrine therapy in over 20 years and the only oral therapy specifically indicated for patients with ESR1-mutated advanced or metastatic breast cancer
- Increased awareness of the ESR1 mutation and the unmet treatment need
- Strong media coverage consisting of 763 earned and syndicated articles with over 1.25B unique visitors per month (UVM),
- Strong journalist engagement with 9,243 shares and an audience reach of 1.69M